Department of Infection and Immunity, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Alfaisal University College of Medicine, Riyadh, Saudi Arabia.
Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge, UB8 3PH, United Kingdom.
Immunobiology. 2019 May;224(3):408-418. doi: 10.1016/j.imbio.2019.02.006. Epub 2019 Feb 11.
Hydrophilic lung surfactant proteins have emerged as key immunomodulators which are potent at the recognition and clearance of pulmonary pathogens. Surfactant protein A (SP-A) is a surfactant-associated innate immune molecule, which is known to interact with a variety of pathogens, and display anti-microbial effects. SP-A, being a carbohydrate pattern recognition molecule, has a wide range of innate immune functions against respiratory pathogens, including influenza A virus (IAV). Some pandemic pH1N1 strains resist neutralization by SP-A due to differences in the N-glycosylation of viral hemagglutinin (HA). Here, we provide evidence, for the first time, that a recombinant form of human SP-A (rfhSP-A), composed of α-helical neck and carbohydrate recognition domains, can actually promote the IAV replication, as observed by an upregulation of M1 expression in lung epithelial cell line, A549, when challenged with pH1N1 and H3N2 IAV subtypes. rfhSP-A (10 μg/ml) bound neuraminidase (NA) (∼60 kDa), matrix protein 1 (M1) (∼25 kDa) and M2 (∼17 kDa) in a calcium dependent manner, as revealed by far western blotting, and direct binding ELISA. However, human full length native SP-A downregulated mRNA expression levels of M1 in A549 cells challenged with IAV subtypes. Furthermore, qPCR analysis showed that transcriptional levels of TNF-α, IL-12, IL-6, IFN-α and RANTES were enhanced following rfhSP-A treatment by both IAV subtypes at 6 h post-IAV infection of A549 lung epithelial cells. In the case of full length SP-A treatment, mRNA expression levels of TNF-α and IL-6 were downregulated during the mid-to-late stage of IAV infection of A549 cells. Multiplex cytokine/chemokine array revealed enhanced levels of both IL-6 and TNF-α due to rfhSP-A treatment in the case of both IAV subtypes tested, while no significant effect was seen in the case of IL-12. Enhancement of IAV infection of pH1N1 and H3N2 subtypes by truncated rfhSP-A, concomitant with infection inhibition by full-length SP-A, appears to suggest that a complete SP-A molecule is required for protection against IAV. This is in contrast to a recombinant form of trimeric lectin domains of human SP-D (rfhSP-D) that acts as an entry inhibitor of IAV.
水肺表面活性剂蛋白已成为关键的免疫调节剂,能够识别和清除肺部病原体。表面活性剂蛋白 A(SP-A)是一种与多种病原体相互作用并具有抗微生物作用的表面活性剂相关先天免疫分子。作为一种碳水化合物模式识别分子,SP-A 具有针对呼吸道病原体的广泛先天免疫功能,包括甲型流感病毒(IAV)。由于病毒血凝素(HA)的 N-糖基化存在差异,一些大流行的 pH1N1 株对 SP-A 的中和作用具有抵抗力。在这里,我们首次提供证据表明,一种由α-螺旋颈和碳水化合物识别结构域组成的重组人 SP-A(rfhSP-A)实际上可以促进 IAV 的复制,如肺上皮细胞系 A549 中观察到的 M1 表达上调,当受到 pH1N1 和 H3N2 IAV 亚型的挑战时。rfhSP-A(10μg/ml)以钙依赖性方式结合神经氨酸酶(NA)(∼60kDa)、基质蛋白 1(M1)(∼25kDa)和 M2(∼17kDa),如远 Western 印迹和直接结合 ELISA 所示。然而,全长天然 SP-A 下调了 A549 细胞中 IAV 亚型挑战后 M1 的 mRNA 表达水平。此外,qPCR 分析显示,在 A549 肺上皮细胞感染 IAV 亚型后 6 小时,两种 IAV 亚型的 rfhSP-A 处理均增强了 TNF-α、IL-12、IL-6、IFN-α 和 RANTES 的转录水平。在全长 SP-A 处理的情况下,在 A549 细胞感染 IAV 的中后期,TNF-α 和 IL-6 的 mRNA 表达水平下调。在两种测试的 IAV 亚型中,由于 rfhSP-A 处理,多因子细胞因子/趋化因子阵列显示出 IL-6 和 TNF-α 的水平增强,而 IL-12 则没有明显影响。由于 pH1N1 和 H3N2 亚型的 IAV 感染增强,而全长 SP-A 抑制感染,这似乎表明完整的 SP-A 分子是抵抗 IAV 所必需的。这与作为 IAV 进入抑制剂的三聚体人 SP-D 的 lectin 结构域的重组形式(rfhSP-D)形成对比。